1627 related articles for article (PubMed ID: 12133029)
1. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
Bakris GL; Weir MR
Arch Intern Med; 2000 Mar; 160(5):685-93. PubMed ID: 10724055
[TBL] [Abstract][Full Text] [Related]
3. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
Bandak G; Sang Y; Gasparini A; Chang AR; Ballew SH; Evans M; Arnlov J; Lund LH; Inker LA; Coresh J; Carrero JJ; Grams ME
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724651
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues.
Mangrum AJ; Bakris GL
Semin Nephrol; 2004 Mar; 24(2):168-75. PubMed ID: 15017529
[TBL] [Abstract][Full Text] [Related]
6. What have we learned from the current trials?
Abbott KC; Bakris GL
Med Clin North Am; 2004 Jan; 88(1):189-207. PubMed ID: 14871059
[TBL] [Abstract][Full Text] [Related]
7. Rates and predictors of ACE inhibitor discontinuation subsequent to elevated serum creatinine: a retrospective cohort study.
Jackevicius CA; Wong J; Aroustamian I; Gee M; Mody FV
BMJ Open; 2014; 4(8):e005181. PubMed ID: 25232564
[TBL] [Abstract][Full Text] [Related]
8. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
Maddirala S; Khan A; Vincent A; Lau K
Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
[TBL] [Abstract][Full Text] [Related]
10. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?
Reardon LC; Macpherson DS
Arch Intern Med; 1998 Jan; 158(1):26-32. PubMed ID: 9437375
[TBL] [Abstract][Full Text] [Related]
11. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
Shoda J; Kanno Y; Suzuki H
Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
Sasongko TH; Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2013 Mar; (3):CD009191. PubMed ID: 23543572
[TBL] [Abstract][Full Text] [Related]
13. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
[TBL] [Abstract][Full Text] [Related]
14. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1293-6. PubMed ID: 12133028
[TBL] [Abstract][Full Text] [Related]
15. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
16. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
Schepkens H; Vanholder R; Billiouw JM; Lameire N
Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
[TBL] [Abstract][Full Text] [Related]
17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
18. Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors.
Zuccalà G; Onder G; Pedone C; Cesari M; Marzetti E; Cocchi A; Carbonin P; Bernabei R
Eur J Clin Pharmacol; 2003 Feb; 58(10):695-9. PubMed ID: 12610747
[TBL] [Abstract][Full Text] [Related]
19. ACE inhibitors and ARBs: Managing potassium and renal function.
Momoniat T; Ilyas D; Bhandari S
Cleve Clin J Med; 2019 Sep; 86(9):601-607. PubMed ID: 31498767
[TBL] [Abstract][Full Text] [Related]
20. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
